SCHEMBL333169

SCHEMBL333169

CC(C)(C)[Si](C)(C)OCCN

nearest known ligand 0.34

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
DUT P33316 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isobutane SCHEMBL28764300 0.93 DUT (0.32) DUT
Monoethanolamine SCHEMBL6040685 0.91 ALDH1A1 (0.35) DUT
SCHEMBL680782 0.86 DUT (0.41) DUT
SCHEMBL12143234 0.86 DUT (0.41) DUT
SCHEMBL1038400 0.85 ODC1 (0.42) DUT
SCHEMBL1785391 0.83 DUT (0.38) DUT
SCHEMBL11580466 0.83 DUT (0.42) DUT
SCHEMBL24387134 0.83 DUT (0.36) DUT
SCHEMBL100630 0.81 DUT (0.37) DUT
SCHEMBL8057981 0.81 DUT (0.37) DUT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 919 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119432181-A Environment-friendly polymer cement waterproof paint and preparation method thereof 佛山市德堡建材有限公司 2025-02-14 CN claimed
CN-114672023-B Preparation method of flexible hyperbranched water-soluble polyimide resin 江苏环峰电工材料有限公司 2023-06-09 CN claimed
CN-114672023-A Preparation method of flexible hyperbranched water-soluble polyimide resin 江苏环峰电工材料有限公司广州分公司 2022-06-28 CN claimed
US-20100125064-A1 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases NOVARTIS AG (CH) 2010-05-20 US claimed
EP-2142535-A2 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis Ag (CH) 2010-01-13 EP claimed
WO-2008119741-A2 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2008-10-09 WO claimed
US-20260137706-A1 METHODS OF TREATING INFLAMMATORY DISEASES INTERLINE THERAPEUTICS INC (US) 2026-05-21 US disclosed
US-20260137703-A1 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER CANCER RESEARCH TECH LIMITED (GB) 2026-05-21 US disclosed
EP-4743462-A1 COMPOUNDS COMPRISING A NAPHTHYRIDINE OR PYRIDOPYRIMIDINE CORE AS PTC READ-THROUGH AGENTS Tay Therapeutics Limited (GB) 2026-05-20 EP disclosed
CN-122055373-A Bridged tricyclic carbamoyl pyridone compounds and uses thereof 吉利德科学公司 2026-05-15 CN disclosed
CN-122055357-A Heterocyclic compound and application thereof 成都麻沸散医药科技有限公司 2026-05-15 CN disclosed
EP-4739652-A1 LIPIDS AND COMPOSITIONS THEREOF Kernal Biologics, Inc. (US) 2026-05-13 EP disclosed
US-20260125384-A1 INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2026-05-07 US disclosed
CN-1248245-A Friable compounds for pathogen inactivation CERUS CORP (US) 2000-03-22 CN disclosed
EP-0960104-A1 N-(AMIDINOPHENYL)-N'-(SUBST.)-3H-2,4-BENZODIAZEPIN-3-ONE DERIVATIVES AS FACTOR XA INHIBITORS Du Pont Pharmaceuticals Company (US) 1999-12-01 EP disclosed
US-5925635-A 2-(OXO-1,3-PERHYDRODIAZEPINES OR 3-OXO-2,3,4,5-TETRAHYDRO-1H-2,4-BENZODIAZEPINES; ANTICOAGULANTS; ENZYME INHIBITORS OF SERINE PROTEASE THROMBIN, KALLIKREIN AND PLASMIN; NERVOUS SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS DUPONT PHARMACEUTICALS COMPANY (US) 1999-07-20 US disclosed
WO-1997038984-A1 N-(AMIDINOPHENYL)-N'-(SUBST.)-3H-2,4-BENZODIAZEPIN-3-ONE DERIVATIVES AS FACTOR XA INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 1997-10-23 WO disclosed
EP-0501693-B1 Isoquinoline derivatives BANYU PHARMA CO LTD (JP) 1996-08-28 EP disclosed
US-5362736-A Alkoxy derivatives for cardiovascular disorders BANYU PHARMACEUTICAL CO., LTD. (JP) 1994-11-08 US disclosed
EP-0501693-A1 Isoquinoline derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 1992-09-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260137703-A1 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER EGFR, KRAS, O60361 DUT 1465/4885
US-20260137706-A1 METHODS OF TREATING INFLAMMATORY DISEASES NR3C1, CCR1, CXCR2 DUT 3936/4885
US-20100125064-A1 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases MDM4, TP53, MDM2 DUT 2418/4885
US-20260125384-A1 INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF CGAS, GMPS, PRKG1 DUT 879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.